Back to results
US 2024/0252594 A1Published application
Combination therapy for neurodegenerative diseases
AssigneeAleta Neuroscience, LLC
InventorAlexander SHTILBANS
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeAleta Neuroscience, LLC
InventorAlexander SHTILBANS
Estimating the term…
This invention provides compositions and methods for treating or preventing neurodegenerative disorders with combinations of at least two drugs from two or more classes of pharmacological activity. The subject neurodegenerative disorders are associated with misfolding of tau proteins, amyloid, alpha-synuclein, superoxide dismutase 1 (SOD1), Tar DNA binding protein-43 (TDP43), Ubiquilin-2, p62, valosin-containing protein (VCP), huntingtin protein (mHtt) and dipeptide repeat (DPR) proteins. The pharmacological classes include a chemical chaperone class of drugs including bile acids, a Heat Shock Proteins (HSP) co-inducer class of drugs, a glucagon-like-peptide-1 agonist (GLP-1) class of drugs, an iron chelator class of drugs, and a cluster-Abelson (c-Abl) tyrosine kinase inhibitor class of drugs.
A method of treating a neurodegenerative disorder or preventing a neurodegenerative disorder selected from Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease (HD), Progressive Supranuclear Palsy (PSP), Frontotemporal dementia (FTD) and Corticobasal Degeneration (CBD), wherein the method consists of the administration of a composition consisting of a combination of two or more drugs selected from at least two distinct pharmacological classes of drugs, wherein the distinct classes of drugs consist of a sodium 4-phenylbutyrate chemical chaperone class of drugs, a bile acid class of drugs, a glucagon-like-peptide-1 agonist (GLP-1) class of drugs, an iron chelator class of drugs, and a cluster-Abelson (c-Abl) tyrosine kinase inhibitor class of drugs.
A method of treating a neurodegenerative disorder or preventing a neurodegenerative disorder associated with misfolding of proteins selected from the group consisting of tau proteins (AD, PSP, CBD), amyloid (AD), alpha-synuclein (PD), superoxide dismutase 1 (SOD1) (ALS), Tar DNA binding protein-43 (TDP43) (ALS), Ubiquilin-2 (ALS), p62 (ALS), valosin-containing protein (VCP) (ALS), mutant huntingtin protein (mHtt) (HD), and dipeptide repeat (DPR) (ALS) proteins, wherein the method consists of the administration of a composition consisting of a combination of two or more drugs selected from at least two distinct pharmacological classes of drugs, wherein the distinct classes of drugs consist of a sodium 4-phenylbutyrate chemical chaperone class of drugs, a bile acid class of drugs, a glucagon-like-peptide-1 agonist (GLP-1) class of drugs, an iron chelator class of drugs, and a cluster-Abelson (c-Abl) tyrosine kinase inhibitor class of drugs.
Dependencies are inferred from the claim text.